{
    "id": "e99af1cd-9dc7-48fb-a51b-b1abcbd1bd72",
    "indications": "clobetasol propionate ointment usp , 0.05 % super-high potency corticosteroid formulations indicated relief inflammatory pruritic manifestations corticosteroid-responsive dermatoses . treatment beyond 2 consecutive weeks recommended , total exceed 50 g/week potential suppress hypothalamic-pituitary- adrenal ( hpa ) axis . pediatric patients 12 years age recommended . highly active corticosteroids , therapy discontinued control achieved . improvement seen within 2 weeks , reassessment diagnosis may necessary .",
    "contraindications": "apply thin layer clobetasol propionate ointment affected skin areas twice daily rub gently completely . ( usage . ) clobetasol propionate ointment super- high potency topical corticosteroids ; therefore , treatment limited 2 consecutive weeks , amounts greater 50 g per week used . highly active corticosteroids , therapy discontinued control achieved . improvement seen within 2 weeks , reassessment diagnosis may necessary . clobetasol propionate ointment used occlusive dressings . geriatric : geriatric patients ( 65 years age older , ) treated clobetasol propionate ointment , safety differ younger patients ; therefore , adjustment recommended .",
    "warningsAndPrecautions": "product : 50090-6731 ndc : 50090-6731-0 30 g tube / 1 carton",
    "adverseReactions": "clobetasol propionate ointment contraindicated patients history hypersensitivity components preparations .",
    "ingredients": [
        {
            "name": "CLOBETASOL PROPIONATE",
            "code": "779619577M"
        },
        {
            "name": "SORBITAN SESQUIOLEATE",
            "code": "0W8RRI5W5A"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "PETROLATUM",
            "code": "4T6H12BN9U"
        }
    ],
    "organization": "A-S Medication Solutions",
    "name": "Clobetasol Propionate",
    "effectiveTime": "20250515",
    "indications_original": "Clobetasol propionate ointment USP, 0.05% is super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary- adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended. \n                      As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.",
    "contraindications_original": "Apply a thin layer of clobetasol propionate ointment to the affected skin areas twice daily and rub in gently and completely. (See INDICATIONS AND USAGE.) \n                      Clobetasol propionate ointment are super- high potency topical corticosteroids; therefore, treatment should be limited to 2 consecutive weeks , and amounts greater than 50 g per week should not be used.\n                      As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Clobetasol propionate ointment should not be used with occlusive dressings.\n                  \n                  \n                  \n                     \n                  \n                  \n                      Geriatric Use: In studies where geriatric patients (65 years of age or older, see PRECAUTIONS) have been treated with clobetasol propionate ointment, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.",
    "warningsAndPrecautions_original": "Product:    50090-6731\n                  NDC:    50090-6731-0   30 g in a TUBE   /  1  in a  CARTON",
    "adverseReactions_original": "Clobetasol propionate ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations."
}